ALX Oncology Reports Q1 Basic EPS of -$0.17, Operating Expenses at $18.97M
ALXO has more than doubled off its 52-week low of $0.404.
Summary
ALX Oncology reported Q1 basic EPS of -$0.17, with operating expenses totaling $18.966 million and a net loss of $17.927 million. This financial update provides insight into the company's cash burn rate and operational efficiency, which are crucial for a clinical-stage biotech. The report follows recent positive news regarding promising drug trial results for its investigational drug evorpacept, and a significant equity offering earlier in the year to extend its cash runway. Traders will monitor these financials to assess the company's ability to fund ongoing drug development and its overall financial health.
At the time of this announcement, ALXO was trading at $1.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $246.1M. The 52-week trading range was $0.40 to $2.66. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.